Long-term outcome of haemophilia A patients after successful immune tolerance induction therapy using a single plasma-derived FVIII/VWF product: the long-term ITI study.

Jiménez-Yuste, V; Oldenburg, J; Rangarajan, S; Peiró-Jordán, R; Santagostino, E

Jiménez-Yuste, V; Oldenburg, J; Rangarajan, S; Peiró-Jordán, R; Santagostino, E.

Affiliation

Jiménez-Yuste V; Haematology Department, Hospital Universitario La Paz, Universidad Autónoma de Madrid, Madrid, Spain.
Oldenburg J; University Clinic Bonn, Institute of Experimental Haematology and Transfusion Medicine, Bonn, Germany.
Rangarajan S; Haemophilia, Haemostasis & Thrombosis Centre, Hampshire Hospitals NHS Foundation Trust, Basingstoke, UK.
Peiró-Jordán R; Scientific and Medical Affairs Department, Grifols, Sant Cugat del Vallès, Barcelona, Spain.
Santagostino E; Centro Emofilia e Trombosi "Angelo Bianchi Bonomi", Fondazione IRCCS Ca' Granda, Milano, ltalia.

Haemophilia ; 22(6): 859-865, 2016 Nov.

Article in En | MEDLINE | ID: mdl-27329267

Subject(s)

Factor VIII/therapeutic use; Hemophilia A/drug therapy; Immune Tolerance/genetics; von Willebrand Factor/therapeutic use; Adult; Female; Humans; Male; Retrospective Studies; Treatment Outcome; Young Adult

Key words

FVIII inhibitor; coagulation factor VIII; factor concentrate; haemophilia; immune tolerance; long-term

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Factor VIII / Von Willebrand Factor / Hemophilia A / Immune Tolerance Type of study: Observational_studies Limits: Adult / Female / Humans / Male Language: En Journal: Haemophilia Journal subject: HEMATOLOGIA Year: 2016 Type: Article Affiliation country: Spain

Fulltext

XML

PubMed Links

Search on Google